Compare Cytokinetics Inc (CYTK) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Nutrien Ltd — how do they compare? Cytokinetics Inc trades at $77.22 (market cap $10.63B), while Nutrien Ltd trades at $66.73 (market cap $32.05B). The key difference: Nutrien Ltd is far larger — about 3× Cytokinetics Inc's market cap, and Nutrien Ltd pays a 3.27% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | NTR | |
|---|---|---|
Market Cap | $10.63B | $32.05B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $83.94 |
52-Week Low | $34.31 | $53.64 |
Enterprise Value | $10.74B | $43.86B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Nutrien (NTR) trades at $66.31, up 2.93% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $2.61 per share, missing estimates, though revenues benefited from higher potash prices. Fundamentals show solid profitability with 8.44% net margin and reasonable valuation at P/E of 13.62. Recent dividend declarations of $0.55 per share demonstrate shareholder returns commitment.
NTR presents value opportunity with analyst consensus target of $76.17 (15% upside) and strong buy ratings (61%). However, earnings volatility, declining cash flow trends, and agricultural cycle sensitivity pose risks. The stock's appeal hinges on execution amid input cost pressures and global fertilizer demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
